Biolex Therapeutics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2011 | $6 M | No. 3 | $2 to $10 million | debt, options | SEC | |
| Jul 2010 | $9 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Feb 2010 | $10 M | No. 1 | $10 to $50 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Biolex Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2011).
SEC Form D · Jun 2011
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2011
That is all the official record says: Biolex Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Biolex Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dale A. Sander | Executive officer | Jun 2011 |
| David P. Spencer | Executive officer | Jun 2011 |
| Jan P. Turek | Executive officer | Jun 2011 |
| Kurt Page Graves | Executive officer | Jun 2011 |
| Glen A. Williams | Executive officer | Jul 2010 |
| David L. Castaldi | Director | Jun 2011 |
| Dennis J. Dougherty | Director | Jun 2011 |
| Jan P. Turek | Director | Jun 2011 |
| Jeffrey Thomas Leiden | Director | Jun 2011 |
| Kevin A. Bitterman | Director | Jun 2011 |
| Klaus Thomas Veitinger | Director | Jun 2011 |
| Kurt Page Graves | Director | Jun 2011 |
| Liza Page Nelson | Director | Jun 2011 |
| P. Sherrill Neff | Director | Jun 2011 |
| W. Thomas Amick | Director | Jun 2011 |
| David Sherrill Castaldi | Director | Jul 2010 |
| Jeff Thomas Leiden | Director | Jul 2010 |
| Liza Sherrill Page Nelson | Director | Jul 2010 |